These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. Slowinska-Srzednicka J; Zgliczynski S; Jeske W; Stopinska-Gluszak U; Srzednicki M; Brzezinska A; Zgliczynski W; Sadowski Z J Endocrinol Invest; 1992; 15(7):533-8. PubMed ID: 1280287 [TBL] [Abstract][Full Text] [Related]
66. Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. Gibney J; Johannsson G; Leung KC; Ho KK J Clin Endocrinol Metab; 2005 Jul; 90(7):3897-903. PubMed ID: 15855258 [TBL] [Abstract][Full Text] [Related]
67. Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females--a general clinical research center-based study. Veldhuis JD; Roemmich JN; Rogol AD J Clin Endocrinol Metab; 2000 Jul; 85(7):2385-94. PubMed ID: 10902783 [TBL] [Abstract][Full Text] [Related]
68. The effects of estrogen and progesterone on the functional capacity of the gonadotrophs. Lasley BL; Wang CF; Yen SS J Clin Endocrinol Metab; 1975 Nov; 41(5):820-6. PubMed ID: 1102551 [TBL] [Abstract][Full Text] [Related]
69. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. Weissberger AJ; Ho KK; Lazarus L J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807 [TBL] [Abstract][Full Text] [Related]
70. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Garcia JM; Polvino WJ Growth Horm IGF Res; 2009 Jun; 19(3):267-73. PubMed ID: 19196529 [TBL] [Abstract][Full Text] [Related]
71. Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy. Veldhuis JD; Keenan DM; Mielke K; Miles JM; Bowers CY Eur J Endocrinol; 2005 Oct; 153(4):577-86. PubMed ID: 16189179 [TBL] [Abstract][Full Text] [Related]
72. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Veldhuis JD J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385 [TBL] [Abstract][Full Text] [Related]
73. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages. Bellantoni MF; Harman SM; Cho DE; Blackman MR J Clin Endocrinol Metab; 1991 Jan; 72(1):172-8. PubMed ID: 1824707 [TBL] [Abstract][Full Text] [Related]
74. Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus. de Sá LB; Nascif SO; Correa-Silva SR; Molica P; Vieira JG; Dib SA; Lengyel AM Metabolism; 2010 Oct; 59(10):1536-42. PubMed ID: 20189610 [TBL] [Abstract][Full Text] [Related]
75. Ghrelin does not mediate the somatotroph and corticotroph responses to the stimulatory effect of glucagon or insulin-induced hypoglycaemia in humans. Broglio F; Prodam F; Gottero C; Destefanis S; Me E; Riganti F; Giordano R; Picu A; Balbo M; Van der Lely AJ; Ghigo E; Arvat E Clin Endocrinol (Oxf); 2004 Jun; 60(6):699-704. PubMed ID: 15163333 [TBL] [Abstract][Full Text] [Related]
76. Changes in serum immunoreactive and bioactive growth hormone concentrations in boys with advancing puberty and in response to a 20-hour estradiol infusion. Cemeroglu AP; Barkan AL; Kletter GB; Beitins IZ; Foster CM J Clin Endocrinol Metab; 1997 Jul; 82(7):2166-71. PubMed ID: 9215289 [TBL] [Abstract][Full Text] [Related]
77. Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men. Veldhuis JD; Keenan DM Eur J Endocrinol; 2008 Nov; 159(5):547-54. PubMed ID: 18703567 [TBL] [Abstract][Full Text] [Related]
78. Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease. Aziz NA; Pijl H; Frölich M; Schröder-van der Elst JP; van der Bent C; Roelfsema F; Roos RA Eur J Neurol; 2010 Feb; 17(2):280-8. PubMed ID: 19845749 [TBL] [Abstract][Full Text] [Related]
79. Increased serum levels of growth hormone and insulin-like growth factor-I associated with simultaneous decrease of circulating insulin in postmenopausal women receiving hormone replacement therapy. Fonseca E; Ochoa R; Galván R; Hernández M; Mercado M; Zárate A Menopause; 1999; 6(1):56-60. PubMed ID: 10100181 [TBL] [Abstract][Full Text] [Related]
80. Effects of long-term erythropoietin therapy on the hypothalamo-pituitary-testicular axis in male CAPD patients. Tokgöz B; Utaş C; Dogukan A; Güven M; Taşkapan H; Oymak O; Keleştimur F Perit Dial Int; 2001; 21(5):448-54. PubMed ID: 11757827 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]